Dupixent (dupilumab) — Medica

Initial criteria

• age ≥ 18 years
• Prescribed by or in consultation with a dermatologist

Reauthorization criteria

• Patient has already received ≥ 6 months of Dupixent therapy
• Patient has experienced beneficial clinical response (e.g., decreased skin area involvement, lesions/blisters/erosions, urticaria, erythema, or reduced corticosteroid need)

Approval duration

initial 6 months, reauthorization 1 year